Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides

Hims & Hers stock rose 6% on Thursday after gaining 13% Wednesday, as RFK Jr. said the FDA will consider moving seven peptides out of a restricted category and into review by the Pharmacy Compounding Advisory Committee. The development is viewed as positive for Hims & Hers because it has a peptide manufacturing facility and could benefit from broader access to compounded treatments. Despite the two-day bounce, the stock remains down 23% year to date amid ongoing regulatory risk around compounded GLP-1 drugs.

Analysis

The first-order read is bullish for HIMS, but the more important signal is that regulatory optionality is increasing faster than the market can re-underwrite the company’s terminal mix. If even a subset of peptides migrates from a hard prohibition regime to a reviewable/compounding-eligible framework, the valuation debate shifts from "illegal/temporary" to "bounded but expandable," which typically supports multiple expansion before the underlying revenue re-accelerates.

Second-order, the real beneficiary may be the compounding ecosystem and adjacent specialty pharmacies rather than HIMS alone. HIMS has distribution, brand, and a consumer funnel; if the regulatory overhang eases, the scarce asset becomes compliant manufacturing capacity and quality systems, which could compress margins short term as capacity is scaled and audited. That means the near-term upside may be strongest in sentiment, while the medium-term earnings upside depends on how much of the category HIMS can capture without diluting gross margin or inviting another regulatory cycle.

The downside case is that this is still a process headline, not a legal resolution. The market is likely pricing a favorable endpoint months ahead of any durable clarity, leaving HIMS vulnerable to a pullback if the committee narrows the scope, imposes usage constraints, or slows implementation into late summer/fall. For NVO, the direct read-through is minimal near term, but any normalization of peptide access could reduce some consumer-channel friction and make the company’s branded pathway more competitive versus gray-market substitution.

Consensus may be underestimating how much of the move is a short-covering event layered on top of a real fundamental catalyst. But it may also be overestimating timing: the stock can trade as if the issue is resolved, while the actual cash-flow impact likely arrives in stages over 2-3 quarters. That mismatch creates a good setup for tactical longs with tight risk controls rather than a blind chase after a two-day gap up.

Key Decisions for Investors

• Trade HIMS tactically long only on pullbacks: buy weakness over the next 3-10 trading days, target a 15-25% move if regulatory headlines continue, but use a hard stop below the post-news breakout level because this is a sentiment trade before it is an earnings trade.
• Consider HIMS call spreads 1-3 months out instead of outright equity: limited premium outlay captures the regulatory rerating while capping downside if the committee process delays or narrows the scope.
• Pair trade: long HIMS / short a basket of higher-quality consumer-health or telehealth names that are less sensitive to regulatory optionality, to isolate the peptide-access re-rating; close the pair if the spread compresses quickly on follow-through headlines.
• For longer-term investors, wait for confirmation in the next 1-2 quarterly updates before adding size; the key risk is margin dilution from compliance and manufacturing scale-up, which can offset top-line enthusiasm.
• NVO is not a primary trade here, but any move lower on "peptide access" headlines looks like a buyable dip only if it coincides with evidence of channel share loss; absent that, the read-through is too small to justify aggressive shorting.